Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences

December 01, 2025

These are historic days for the company, following its first FDA approval.

Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today ↗

November 26, 2025

Arrowhead Pharmaceuticals Stock Jumps 22% After Morgan Stanley Hikes Price Target ↗

November 26, 2025

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Reports Strong Q4 2025 Revenue Beat and First FDA Approval ↗

November 25, 2025

Arrowhead Pharmaceuticals exceeded Q4 2025 revenue expectations, driven by its first FDA-approved drug and strong collaborations, marking its shift to a commercial-stage company.

Via Chartmill

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript ↗

November 25, 2025

Arrowhead (ARWR) Q4 2025 Earnings Call Transcript

Topics Earnings

Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results

November 25, 2025

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

November 24, 2025

Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 19, 2025

Via Benzinga

FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder ↗

November 18, 2025

Via Benzinga

Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

November 18, 2025

CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial ↗

November 11, 2025

CRISPR Therapeutics' CTX310 trial shows strong, sustained lipid reductions and favorable safety, boosting confidence in its gene editing platform.

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results

November 06, 2025

Privium Fund Management Sells Into Strength in Pharma Stock

Privium Fund Management Sells Into Strength in Pharma Stock ↗

November 04, 2025

Topics Regulatory Compliance

Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences

November 04, 2025

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

October 28, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

October 07, 2025

From Arrowhead Pharmaceuticals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗

September 29, 2025

Via Benzinga

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 11, 2025

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

September 10, 2025

The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 02, 2025

Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences

August 27, 2025

This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week ↗

August 14, 2025

H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s closing price on Wednesday.

Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquified its entire stake in the company.

Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives ↗

August 14, 2025

Via Investor's Business Daily

Topics Death

Sarepta Keeps Retail Traders Bullish As Stock Surges On $100M Milestone Payment To Arrowhead In Genetic Disorder Trial ↗

August 14, 2025

Sarepta sold part of its Arrowhead stake to help fund the milestone payment, while also outlining plans to release early data from two genetic therapy programs in the second half of 2025.